<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002045'>Hypothermia</z:hpo> is robustly protective in pre-clinical models of both global and focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, as well as in patients after <z:hpo ids='HP_0001695'>cardiac arrest</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Although the mechanism for hypothermic neuroprotection remains unknown, reducing metabolic drive may play a role </plain></SENT>
<SENT sid="2" pm="."><plain>Capitalizing on the beneficial effects of <z:hpo ids='HP_0002045'>hypothermia</z:hpo> while avoiding detrimental effects such as <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> will be the key to moving this therapy forward as a treatment for <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>AMPK is a master energy sensor that monitors levels of key energy metabolites </plain></SENT>
<SENT sid="4" pm="."><plain>AMPK is activated via phosphorylation (pAMPK) when cellular energy levels are low, such as that seen during <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>AMPK activation appears to be detrimental in experimental <z:hpo ids='HP_0001297'>stroke</z:hpo>, likely via exacerbating <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced metabolic failure </plain></SENT>
<SENT sid="6" pm="."><plain>We tested the hypothesis that <z:hpo ids='HP_0002045'>hypothermia</z:hpo> reduces AMPK activation </plain></SENT>
<SENT sid="7" pm="."><plain>First, it was found that <z:hpo ids='HP_0002045'>hypothermia</z:hpo> reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> after middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>Second, induced <z:hpo ids='HP_0002045'>hypothermia</z:hpo> reduced brain pAMPK in both sham control and <z:hpo ids='HP_0001297'>stroke</z:hpo> mice </plain></SENT>
<SENT sid="9" pm="."><plain>Third, hypothermic neuroprotection was ameliorated after administration of compound C, an AMPK inhibitor </plain></SENT>
<SENT sid="10" pm="."><plain>Finally, deletion of one of the catalytic isoforms of AMPK completely reversed the effect of <z:hpo ids='HP_0002045'>hypothermia</z:hpo> on <z:hpo ids='HP_0001297'>stroke</z:hpo> outcome after both <z:hpo ids='HP_0011009'>acute</z:hpo> and <z:hpo ids='HP_0011010'>chronic</z:hpo> survival </plain></SENT>
<SENT sid="11" pm="."><plain>These effects were mediated by a reduction in AMPK activation rather than a reduction in LKB1, an upstream AMPK kinase </plain></SENT>
<SENT sid="12" pm="."><plain>In summary, these studies provide evidence that <z:hpo ids='HP_0002045'>hypothermia</z:hpo> exerts its protective effect in part by inhibiting AMPK activation in experimental focal <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="13" pm="."><plain>This suggests that AMPK represents a potentially important biological target for <z:hpo ids='HP_0001297'>stroke</z:hpo> treatment </plain></SENT>
</text></document>